NPTX

Neuropathix (QB) Stock Price

0.20
0.04 (25.0%)
0.20
Best deals to access real time data!
Small Cap Basic
Monthly Subscription
for only
$33.03
Ultimate Trader (Monthly)
Monthly Subscription
for only
$80.29
DDE w/Realtime (Monthly)
Monthly Subscription
for only
$34.10
VAT not included
Company Name Stock Ticker Symbol Market Type
Neuropathix Inc (QB) NPTX OTCMarkets Common Stock
  Price Change Change Percent Stock Price Last Traded
0.04 25.0% 0.20 15:18:38
Open Price Low Price High Price Close Price Prev Close
0.16 0.142 0.20 0.20 0.16
Bid Price Ask Price Spread News
0.195 0.21 0.015 - -
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
28 74,955 $ 0.173028 $ 12,969 - 0.13 - 0.805
Last Trade Time Type Quantity Stock Price Currency
15:17:18 6,500 $ 0.20 USD

Neuropathix (QB) Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 15.05M 75.25M 10.92M $ - $ - - -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
7.60k $ - 0.00% - -

more financials information »

Neuropathix (QB) News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical NPTX Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.180.200.130.1556588114,2320.0211.11%
1 Month0.240.240.130.167491360,075-0.04-16.67%
3 Months0.330.8050.130.21916640,610-0.13-39.39%
6 Months0.330.8050.130.21916640,610-0.13-39.39%
1 Year0.330.8050.130.21916640,610-0.13-39.39%
3 Years0.330.8050.130.21916640,610-0.13-39.39%
5 Years0.330.8050.130.21916640,610-0.13-39.39%

Neuropathix (QB) Description

Neuropathix, Inc., formerly Kannalife, Inc. ("Neuropathix"), is a socially responsible pain management life sciences company. For the past ten years, Neuropathix has discovered, developed and patented a global intellectual property estate of novel new therapeutic agents designed to prevent and reverse neuropathic pain, reduce oxidative stress, and act as anti-inflammatory neuroprotectants. Neuropathix was the only company to hold an exclusive license with National Institutes of Health - Office of Technology Transfer ("NIH-OTT") for the Commercialization of U.S. Patent #6630507, "Cannabinoids as Antioxidants and Neuroprotectants" (the "'507 Patent"). This early and extensive pre-clinical research on cannabidiol (CBD) led Neuropathix to develop its own patented molecules lead by KLS-13019 called by Sports Illustrated as a "super-CBD" and currently covered under global patents awarded including U.S. Patent #9611213, "Functionalized 1,3-benzene diols and their method of use for the treatment of hepatic encephalopathy". Neuropathix continues to conduct its research and development efforts at the Bucks County Pennsylvania Biotechnology Center in Doylestown, PA, for a target drug candidate to treat Hepatic Encephalopathy ("HE"), Chronic Traumatic Encephalopathy ("CTE") and Chemotherapy Induced Peripheral Neuropathy ("CIPN").


Your Recent History
USOTC
NPTX
Neuropathi..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.